Abstract B212: QTc study of picoplatin with emphasis on pharmacodynamics of cardiac repolarization
Autor: | Claire F. Verschraegen, Lorrin Yee, Lee S. Rosen, Steven C. Plaxe, Robert H. Earhart, Robert De Jager, Philip Gold, David S. Mendelson, Scott Houston, Angelica Phillips, Saleh Mansoor |
---|---|
Rok vydání: | 2009 |
Předmět: |
ST depression
Cancer Research medicine.medical_specialty Holter monitor medicine.diagnostic_test business.industry Cmax QT interval Confidence interval Picoplatin QRS complex chemistry.chemical_compound Oncology chemistry Internal medicine Pharmacodynamics medicine Cardiology medicine.symptom business |
Zdroj: | Molecular Cancer Therapeutics. 8:B212-B212 |
ISSN: | 1538-8514 1535-7163 |
DOI: | 10.1158/1535-7163.targ-09-b212 |
Popis: | Introduction: Clinical studies have demonstrated that picoplatin (Pico), a new-generation platinum analogue designed to overcome platinum resistance, has activity when administered IV in solid tumors patients (pts); over 1,100 pts have received pico. The primary toxicity is hematological. Clinically significant nephro-, oto-, or neurotoxicity has rarely been observed ( Methods: The effect of pico on the QT/QTc interval as measured by the ECG was evaluated. The correlation between the QTcF interval and platinum concentration in plasma and plasma ultrafiltrate (PUF) was evaluated. ECG was recorded continuously with a Holter monitor. Triplicate 20 second ECG readings were extracted at 3 times before (baseline reference) and at 8 times in the 24 hrs after pico administration in Cycle 1. Triplicate 12-lead ECGs were obtained at the end of the pico infusion in subsequent cycles. Blood samples were collected before study drug administration and immediately after each ECG timepoint in Cycle 1 for pharmacokinetic analysis. The primary endpoint was the Fredericia corrected QT (QTcF). Time-averaged and time point analyses for QTcF were performed. Heart rate, PR, QRS, QT, QTcB (Bazett's) and morphological changes were also evaluated. Results: 45 pts (28 women and 17 men), age 44–79 years (median = 60) received 150 mg/m2 pico as a 1-hr IV infusion. The time-averaged mean change from baseline of QTcF duration during Cycle 1 was +2.2 ms, which is considered a nonsignificant increase. At each time point in Cycle 1 and in subsequent cycles, there were only minimal changes from baseline in QTcF duration. Other ECG changes from baseline were unremarkable: ST depression was noted in 9% of pts at baseline and new T-wave changes in 7% of pts in Cycle 1. Mean ± SD Cmax in plasma and PUF were 5566 ± 1079 ng/mL and 4034 ± 674 ng/mL, respectively. The change in QTcF vs. platinum concentration in plasma or PUF showed a Cmax effect of 5–6 ms with an upper confidence interval of 8–9 ms, suggesting no clear effect of picoplatin on QTcF. Conclusions: Pico had no effect on the QTcF interval or any other ECG parameter, supporting the clinical data showing that Pico does not increase the risk of serious ventricular arrhythmias. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B212. |
Databáze: | OpenAIRE |
Externí odkaz: |